VX-668
/ Vertex
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 15, 2024
A Phase 1, First-in-human Study of VX-668
(clinicaltrials.gov)
- P1 | N=114 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed
Trial completion • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases
January 01, 2024
A Phase 1, First-in-human Study of VX-668
(clinicaltrials.gov)
- P1 | N=114 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
Trial completion date • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases
November 19, 2023
A Phase 1, First-in-human Study of VX-668
(clinicaltrials.gov)
- P1 | N=114 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Trial primary completion date: Jan 2024 ➔ Sep 2023
Trial primary completion date • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases
March 06, 2023
A Phase 1, First-in-human Study of VX-668
(clinicaltrials.gov)
- P1 | N=114 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting
Enrollment open • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases
February 14, 2023
A Phase 1, First-in-human Study of VX-668
(clinicaltrials.gov)
- P1 | N=114 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated
New P1 trial • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hepatology • Pulmonary Disease • Respiratory Diseases
1 to 5
Of
5
Go to page
1